GlobeNewswire

PSAV® and The Freeman Company Announce Purchase Agreement for PSAV to Acquire Encore Event Technologies

Del

SCHILLER PARK, IL, and DALLAS,TX, Jan. 14, 2019 (GLOBE NEWSWIRE) -- PSAV, a global leader in event experiences, and The Freeman Company, jointly announced today that the companies have entered into a purchase agreement for PSAV to acquire Encore Event Technologies, a global provider of event technology, staging and production services.  The combination of PSAV and Encore will join two companies with deep expertise and a shared commitment to be an invaluable global partner for the meeting industry.  This transaction reinforces PSAV’s mission of Connecting and Inspiring People by expanding the breadth of its capabilities throughout North America and Asia Pacific.  The transaction is expected to be finalized later this year. Terms of the transaction will not be disclosed.

Encore has a long and distinguished history dedicated to helping create high-impact meetings and live events for the hospitality industry. Encore operates as both an in-house partner to some of the world’s leading resorts, hotels and casinos, as well as a creative production company for clients around the world.

“Encore is an ideal partner for the PSAV family of companies given its shared commitment to meeting and event planners, and strong alignment with our purpose and mission,” said Mike McIlwain, CEO of PSAV.  I am excited about what this means for PSAV, and more importantly our customers, as we continue to focus on more ways to create amazing event experiences wherever an event is held.” 

“We’re extremely proud of the success everyone at Encore – including our FAV Canada operations – has created in building one of the world’s leading in-house hospitality, event technology and production service businesses,” said Joe Popolo, CEO of The Freeman Company. “At Freeman, we continue our mission to provide powerful brand experiences, which include our audio visual solutions, for association and corporate customers around the world.”

“It has been an honor to lead and develop Encore and to witness its growth,” said Ken Sanders, chief development officer, The Freeman Company. “I want to thank everyone at Encore for applying their work, skills, dedication and creativity to build this world-class company, and I look forward to watching their continued prosperity as part of PSAV."

Peter Wallace and David Kestnbaum of Blackstone’s Private Equity team commented, “We are excited about the combination of our portfolio company, PSAV, with Encore.  Blackstone sees continued growth opportunities in live events, and we are pleased that Encore will bring additional capabilities to support event planners and our venue partners.”

Bill Stein of Blackstone's Real Estate team added, “The combination of PSAV and Encore will further enhance our strong capabilities to serve meeting event planners and our venue partners across a diverse suite of services as part of our mission of creating a world-class, diversified global live events platform."

Simpson Thacher & Bartlett LLP is serving as legal counsel to PSAV. 

JP Morgan is serving as financial advisor to Freeman and Encore, and Baker McKenzie is serving as legal counsel to Freeman and Encore.

 

About PSAV®

PSAV is a global leader in event experiences, providing creative, production, advanced technology and staging services to help meeting professionals deliver more dynamic and impactful experiences at their meetings, trade shows and events. The team consists of more than 9,000 professionals across 1,500 on-site venue locations and 49 branch offices within the United States, Canada, Mexico, Europe, the Caribbean, and the Middle East. It is the trusted partner and on-site provider of choice at leading venues worldwide. PSAV was recently named to the Forbes 2018 America’s Best Employer list. The company is headquartered in Schiller Park, Ill.  www.psav.com.

 

 

About The Freeman Company

The Freeman Company helps create meaningful connections for all types of global audiences. The family-owned company is comprised of leading brand experience company, Freeman; audio-visual and production company, Encore Event Technologies; and Alford Media, a premier event technology specialist known for the expertise and precision on large-scale shows. With more than 90 locations globally and 7,000+ employees who are dedicated to delivering the best experiences and business outcomes possible for their clients — from strategy and design to implementation and results. For more information, visit http://www.freeman.com/

 

 

About Encore Event Technologies

Encore is a leading global provider of audiovisual, event technology, staging and production services.  Encore serves as the in-house provider at more than 460 hotels, casinos, conference centers and resorts in North America and Asia Pacific.  Encore Productions, the production division of Encore Event Technologies, is a full-service creative production company helping clients tell their stories around the world.  For more information, visit www.encore-us.com, www.encore-anzpac.com and www.freemanav-ca.com.

Attachment

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist